Cargando…

Initial Risk Assessment in Patients with Alveolar Echinococcosis—Results from a Retrospective Cohort Study

Background: Alveolar echinococcosis (AE) is a potentially lethal parasitosis with a broad spectrum of disease dynamics in affected patients. To guide clinical management, we assessed initial prognostic factors for both progressive and controlled AE based on initial staging. Methods: A retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Lynn, Burkert, Sanne, Hagemann, Jürgen Benjamin, Albes, Rasmus, Klemptner, Jonas, Birkle, Jessica, Schwaibold, Elias, Siefermann, Sofia, Grüner, Beate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144025/
https://www.ncbi.nlm.nih.gov/pubmed/35631078
http://dx.doi.org/10.3390/pathogens11050557
_version_ 1784715948509364224
author Peters, Lynn
Burkert, Sanne
Hagemann, Jürgen Benjamin
Albes, Rasmus
Klemptner, Jonas
Birkle, Jessica
Schwaibold, Elias
Siefermann, Sofia
Grüner, Beate
author_facet Peters, Lynn
Burkert, Sanne
Hagemann, Jürgen Benjamin
Albes, Rasmus
Klemptner, Jonas
Birkle, Jessica
Schwaibold, Elias
Siefermann, Sofia
Grüner, Beate
author_sort Peters, Lynn
collection PubMed
description Background: Alveolar echinococcosis (AE) is a potentially lethal parasitosis with a broad spectrum of disease dynamics in affected patients. To guide clinical management, we assessed initial prognostic factors for both progressive and controlled AE based on initial staging. Methods: A retrospective cohort study was conducted, examining 279 patients assigned to different clinical groups: cured, stable with and without the need for benzimidazole treatment, and progressive disease. Univariate analysis compared demographic and clinical variables. Significant variables were subsequently entered into two separate logistic regression models for progressive and controlled disease. Results: Based on the multivariate analysis, a large AE lesion (OR = 1.02 per millimetre in size; 95%CI 1.004–1.029), PNM staging (OR = 2.86; 95%CI 1.384–5.911) and especially the involvement of neighbouring organs (OR = 3.70; 95%CI 1.173–11.653) remained significant risk factors for progressive disease. A negative Em2+ IgG (OR = 0.25; 95%CI 0.072–0.835) and a small AE lesion (OR = 0.97; 95%CI 0.949–0.996) were significant protective factors. Conclusions: Patients with large lesions and advanced stages should be monitored closely and most likely require long-term treatment with benzimidazoles if curative resection is not feasible. Patients with small lesions and negative Em2+ IgG seem able to control the disease to a certain extent and a less strict treatment regimen might suffice.
format Online
Article
Text
id pubmed-9144025
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91440252022-05-29 Initial Risk Assessment in Patients with Alveolar Echinococcosis—Results from a Retrospective Cohort Study Peters, Lynn Burkert, Sanne Hagemann, Jürgen Benjamin Albes, Rasmus Klemptner, Jonas Birkle, Jessica Schwaibold, Elias Siefermann, Sofia Grüner, Beate Pathogens Article Background: Alveolar echinococcosis (AE) is a potentially lethal parasitosis with a broad spectrum of disease dynamics in affected patients. To guide clinical management, we assessed initial prognostic factors for both progressive and controlled AE based on initial staging. Methods: A retrospective cohort study was conducted, examining 279 patients assigned to different clinical groups: cured, stable with and without the need for benzimidazole treatment, and progressive disease. Univariate analysis compared demographic and clinical variables. Significant variables were subsequently entered into two separate logistic regression models for progressive and controlled disease. Results: Based on the multivariate analysis, a large AE lesion (OR = 1.02 per millimetre in size; 95%CI 1.004–1.029), PNM staging (OR = 2.86; 95%CI 1.384–5.911) and especially the involvement of neighbouring organs (OR = 3.70; 95%CI 1.173–11.653) remained significant risk factors for progressive disease. A negative Em2+ IgG (OR = 0.25; 95%CI 0.072–0.835) and a small AE lesion (OR = 0.97; 95%CI 0.949–0.996) were significant protective factors. Conclusions: Patients with large lesions and advanced stages should be monitored closely and most likely require long-term treatment with benzimidazoles if curative resection is not feasible. Patients with small lesions and negative Em2+ IgG seem able to control the disease to a certain extent and a less strict treatment regimen might suffice. MDPI 2022-05-09 /pmc/articles/PMC9144025/ /pubmed/35631078 http://dx.doi.org/10.3390/pathogens11050557 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Peters, Lynn
Burkert, Sanne
Hagemann, Jürgen Benjamin
Albes, Rasmus
Klemptner, Jonas
Birkle, Jessica
Schwaibold, Elias
Siefermann, Sofia
Grüner, Beate
Initial Risk Assessment in Patients with Alveolar Echinococcosis—Results from a Retrospective Cohort Study
title Initial Risk Assessment in Patients with Alveolar Echinococcosis—Results from a Retrospective Cohort Study
title_full Initial Risk Assessment in Patients with Alveolar Echinococcosis—Results from a Retrospective Cohort Study
title_fullStr Initial Risk Assessment in Patients with Alveolar Echinococcosis—Results from a Retrospective Cohort Study
title_full_unstemmed Initial Risk Assessment in Patients with Alveolar Echinococcosis—Results from a Retrospective Cohort Study
title_short Initial Risk Assessment in Patients with Alveolar Echinococcosis—Results from a Retrospective Cohort Study
title_sort initial risk assessment in patients with alveolar echinococcosis—results from a retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144025/
https://www.ncbi.nlm.nih.gov/pubmed/35631078
http://dx.doi.org/10.3390/pathogens11050557
work_keys_str_mv AT peterslynn initialriskassessmentinpatientswithalveolarechinococcosisresultsfromaretrospectivecohortstudy
AT burkertsanne initialriskassessmentinpatientswithalveolarechinococcosisresultsfromaretrospectivecohortstudy
AT hagemannjurgenbenjamin initialriskassessmentinpatientswithalveolarechinococcosisresultsfromaretrospectivecohortstudy
AT albesrasmus initialriskassessmentinpatientswithalveolarechinococcosisresultsfromaretrospectivecohortstudy
AT klemptnerjonas initialriskassessmentinpatientswithalveolarechinococcosisresultsfromaretrospectivecohortstudy
AT birklejessica initialriskassessmentinpatientswithalveolarechinococcosisresultsfromaretrospectivecohortstudy
AT schwaiboldelias initialriskassessmentinpatientswithalveolarechinococcosisresultsfromaretrospectivecohortstudy
AT siefermannsofia initialriskassessmentinpatientswithalveolarechinococcosisresultsfromaretrospectivecohortstudy
AT grunerbeate initialriskassessmentinpatientswithalveolarechinococcosisresultsfromaretrospectivecohortstudy